New hope for throat cancer: testing a powerful immune drug against standard treatment
NCT ID NCT03383094
Summary
This study is testing whether a newer immunotherapy drug (pembrolizumab) combined with radiation works better than the current standard treatment of chemotherapy plus radiation for people with advanced head and neck cancer. It will involve 126 patients whose cancer is linked to the HPV virus (p16-positive). The main goal is to see which treatment better prevents the cancer from growing back or spreading.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center & Research Facility
Tampa, Florida, 33612, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Arizona Cancer Center
Tucson, Arizona, 85719, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37203, United States
-
Washington University School of Medicine, Siteman Cancer Center
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.